Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Adsorbed Cell-free DTP Vaccine (Tdcp)
NCT06708286Phase 3Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed in diphtheria, Tetanus, pertussis, sponsored by CanSino Biologics Inc.. Started Dec 2024; status: completed.
02
Drugs
Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT06708286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708286.